Copy Number Variation in CHRNA7 Gene in Migraine and Gene Expression

Sponsor
University of Gaziantep (Other)
Overall Status
Completed
CT.gov ID
NCT04912752
Collaborator
(none)
200
1
2
8.9
22.4

Study Details

Study Description

Brief Summary

Migraine is a common and possible hereditary disease. Copy number variation (CNV) is a phenomenon in which parts of the genome are repeated and the number of repeats in the genome varies between individuals in the human population.The CHRNA7 gene has a major role in the neuropsychiatric phenotypes observed in patients. The 15q13.3 gain/loss variation in this gene may be associated with migraine.

Condition or Disease Intervention/Treatment Phase
  • Genetic: Migraine CNV
N/A

Detailed Description

Migraine is a common neurological disorder. Although they have different genetic bases according to their types, cholinergic receptors after calcium channels play an important role in the clinic and genetics of the disease. Neuronal acetylcholine receptor subunit alpha-7, also known as nAChRα7, is a protein that in humans is encoded by the CHRNA7 gene.

Study Design

Study Type:
Interventional
Actual Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Basic Science
Official Title:
Copy Number Variation in Migraine and Gene Expression
Actual Study Start Date :
Apr 5, 2020
Actual Primary Completion Date :
Dec 10, 2020
Actual Study Completion Date :
Jan 2, 2021

Arms and Interventions

Arm Intervention/Treatment
Other: Case-Control

Copy number variation

Genetic: Migraine CNV
Copy number variation effect on migraine disease

Experimental: Case-Control 1

Gene expression

Genetic: Migraine CNV
Copy number variation effect on migraine disease

Outcome Measures

Primary Outcome Measures

  1. CNV number [1 year]

    CNV number effect on migraine

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

Migraine

Exclusion Criteria:

Vascular problems

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medicine Gaziantep Şehitkamil Turkey 27310

Sponsors and Collaborators

  • University of Gaziantep

Investigators

  • Principal Investigator: Mehmet Fatih Özaltun, MD, Assist

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Şenay Görücü Yılmaz, Assoc. Prof., University of Gaziantep
ClinicalTrials.gov Identifier:
NCT04912752
Other Study ID Numbers:
  • 2020/12
First Posted:
Jun 3, 2021
Last Update Posted:
Jun 3, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 3, 2021